Halozyme Therapeutics, Inc. Common Stock (NASDAQ: HALO) last traded at $108.17, up 1.93% on the session. The quote above updates while this page is open; the figures below are drawn from Halozyme Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Halozyme Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker HALO. Its market capitalisation is $12.28 billion.
Valuation measures for Halozyme Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $12.28B |
|---|---|
| Enterprise value | $14.55B |
| P/E ratio | 31.63 |
| Price / sales | 7.38 |
| Price / book | 85.53 |
| Beta | 0.54 |
Trailing-twelve-month figures tagged in Halozyme Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $1.66B |
|---|---|
| Net income (TTM) | $413.60M |
| EPS (TTM) | $3.42 |
| Operating margin | 35.90% |
| Return on equity | 288.13% |
| Cash | $163.14M |
Range and volume for HALO over the past 52 weeks.
| 52-week high | $108.49 |
|---|---|
| 52-week low | $61.23 |
| Volume | 1.15M |
| Average volume | 2.01M |
| Previous close | $106.12 |
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.